Current Treatment Options: The standard treatment for Lyme disease primarily involves antibiotics, which can be effective but may have limitations in certain cases, particularly in patients with persistent symptoms post-treatment.
Unmet Need: Many patients experience lingering symptoms, leading to the concept of Post-treatment Lyme Disease Syndrome (PTLDS). A new drug addressing these symptoms could capture significant market interest during the forecast period. Furthermore, the vaccine development is one of the areas for Lyme disease where many global players are making an effort through pre-clinical and clinical studies.
Emerging Lyme disease treatment drugs and vaccine includes;
INCREASING PREVALENCE AN DINCIDENCE OF LYME DISEASE TO DRIVE THE TREATMENT MARKET
Lyme disease, mainly caused by the Borrelia burgdorferi bacterium from tick bites, has seen a significant rise in reported cases. The CDC estimates over 476,000 cases annually in the U.S., underscoring the growing public health concern. This surge has led to increased awareness and investment in research for effective treatments. Overall, the rising incidence of Lyme disease is set to significantly drive the market for its treatments. As awareness grows and healthcare systems adapt, the landscape for Lyme disease solutions is evolving, promising benefits for both patients and healthcare providers.
ANTIBIOTICS – THE FIRST LINE OF TREATMENT FOR LYME DISEASE TREATMENT DOMINATED THE SHARE
The Lyme disease market is categorized into several key product types including antibiotics, adjunct therapies, and experimental & novel therapeutics. Each segment plays a crucial role in the management and treatment of Lyme disease, and their growth is influenced by various factors such as disease prevalence, advancements in research, and healthcare infrastructure. Antibiotics segment accounted for the largest share of 63% of the total Lyme disease treatment market in 2023. Large share of the antibiotics segments can be attributed to its first line of therapy in Lyme disease, higher adoption and the choice of healthcare providers. The large share of this segment is further attributed to higher volume sales as compared to other two therapies.
EARLY-STAGE LYME DISEASE HOLDS THE LARGEST SHARE
Based on stages, the Lyme disease treatment market is segmented into Early-Stage Lyme Disease, Disseminated Lyme Disease, and Chronic Lyme Disease. Early-Stage Lyme Disease segment accounted for the largest share of 43% of the total Lyme disease treatment market in 2023. Large share of this segment can be attributed to increased public awareness about Lyme disease, enhancements in diagnostic testing, standardized antibiotic protocols, and low risk of complications.
ADULT SEGMENT ACCOUNTS FOR THE LARGEST SHARE, WHILE ELDERLY SEGMENT TO REGISTER HIGH GROWTH OWING TO THE ADOPTION OF EXPERIMENTAL AND NOVEL THERAPEUTICS TO MANAGE CHRONIC SYMPTOMS
The Lyme disease market exhibits distinct characteristics across age groups. Children represent a high-growth segment due to increasing outdoor exposure, while adults account for the largest market share owing to their high incidence rates. Elders are gaining attention as a vulnerable population needing tailored strategies. Understanding these dynamics is essential for developing effective public health interventions, enhancing education and awareness, and optimizing treatment approaches across all age demographics.
NORTH AMERICA AND EUROPE HOLDS MAJORITY OF THE MARKET FOR LYME DISEASE TREATMENT
Based on the region, Lyme disease market is segmented into five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe collectively accounted for 92.7% of the total Lyme disease treatment market. The large share of these regions can be attributed to higher incidence and prevalence of Lyme disease in North America and European region. Comparative incidence of Lyme disease is lower in Asia Pacific, Latin American, and Middle East regions.
PROMINENT PLAYERS ACROSS THE TREATMENT OFFERING FOR LYME DISEASE
MARKET DEFINITION
The Lyme disease treatment market encompasses a range of pharmaceutical products and therapies aimed at preventing, managing, and treating Lyme disease, an infectious disease caused by the bacterium Borrelia burgdorferi, transmitted primarily through tick bites.
KEY OBJECTIVES OF THE STUDY
LYME DISEASE TREATMENT MARKET SEGMENTATION
Note: Other Healthcare Settings include academic and research institutions, teaching universities, etc.
Sources: Company Websites and Wissen Research Analysis
RESEARCH METHODOLOGY
RESEARCH DESIGN
Sources: American Lyme Disease Foundation (ALDF), Lyme Disease Association, Inc. (LDA), Global Lyme Alliance (GLA), International Lyme and Associated Diseases Society (ILADS), The Tick-Borne Disease Alliance (TBDA), Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Food and Drug Administration (FDA), European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), World Health Organization (WHO), Pharmaceutical Research and Manufacturers of America (PhRMA), National Health Service (NHS), Company Website, Annual Reports, SEC Filings, Investor Presentation, Press Releases, Paid Data Sources, Wissen Research Analysis
SECONDARY DATA
The research study involved various secondary sources, directories such as Bloomberg business, Factiva, and Wall Street Journals, white papers, annual reports, company house documents, investor presentation, and SEC filings of the companies.
The secondary research approach has been used to identify and collect information useful for the extensive, technical, market oriented and commercial study of the Lyme disease treatment market. It was also used to obtain important information about key players, market classification, and segments according to industry trends and key developments related to the market perspectives. A database of the key industry leaders has also been prepared using secondary research. Some secondary sources referred are;
PRIMARY PARTICIPANTS FROM DEMAND AND SUPPLY SIDE
Note: Above provided list is non-exhaustive
MARKET SIZE ESTIMATION
Total Market Size: LYME DISEASE TREATMENT Market
The total size of Lyme disease treatment market was determined after data triangulation from four approaches as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.
Approach 1: Supply Side analysis (Revenue Share Analysis)
The following figure shows the overall market size estimation process employed for this study;
Sources: Annual report, SEC Filings, Company Websites, Press Releases, Investor Presentation, Primary Interviews, and Wissen Research Analysis
Report presents a detailed assessment of Lyme disease treatment market and qualitative inputs and insights from WISSEN Research. The research study involved the extensive use of both primary and secondary sources. Various factors affecting the industry have been studies to identify segmentation types, industry trends, the competitive landscape of the market, and key market dynamics (such as drivers, restraints, opportunities, and challenges).
Approach 2: Investor Presentation and Primary interviews
Sources: Annual report, SEC Filings, Company Websites, Press Releases, Investor Presentation, Primary Interviews, and Wissen Research Analysis
SCENARIO-BASED MARKET SIZE ESTIMATION FOR EMERGING VACCINES & NOVEL THERAPEUTICS
Notes: *Reference point LYMErix uptake in the year of launch
**Reference point price of LYMErix for annual vaccination
***Benchmarked with US
****Benchmarked at 75% of the US price
Source: American Lyme Disease Foundation (ALDF), Lyme Disease Association, Inc. (LDA), Global Lyme Alliance (GLA), International Lyme and Associated Diseases Society (ILADS), The Tick-Borne Disease Alliance (TBDA), Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Food and Drug Administration (FDA), European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), World Health Organization (WHO), Pharmaceutical Research and Manufacturers of America (PhRMA), National Health Service (NHS), Company Website, Annual Reports, SEC Filings, Investor Presentation, Press Releases, Paid Data Sources, Wissen Research Analysis
Geographical market assessment (by region and country)
Geographical adoption
By Treatment Type: Splits of the segments were derived by studying the type of treatment used to treat Lyme disease, product offerings by key players, and their adoption by the end users such as hospitals, infectious disease specialists, clinic’s, etc. The split shares and the segmental growth rates obtained from the secondary sources and Wissen Research analysis were further validated through expert interviews.
CAGR projections from market dynamics analysis (2024-2030)
Sources: Annual report, SEC Filings, Company Websites, Press Releases, Investor Presentation, Primary Interviews, and Wissen Research Analysis
CAGR projections parameters (2024 – 2030)
Sources: Annual report, SEC Filings, Company Websites, Press Releases, Investor Presentation, Primary Interviews, and Wissen Research Analysis
Data triangulation involved the combination of primary research, secondary research, and the Wissen Research Analysis. Once the data points are sourced from the secondary market research, we sanitize the data points to make the market sizing and growth forecast more accurate by developing our own assumptions based on the inputs and insights we gather through the primary interviews with the industry experts. Once the data is thoroughly validated through primary interviews from both, demand and supply side of the market, our team of analyst and other team members involved finalize the market sizing and growth forecast.
Source: American Lyme Disease Foundation (ALDF), Lyme Disease Association, Inc. (LDA), Global Lyme Alliance (GLA), International Lyme and Associated Diseases Society (ILADS), The Tick-Borne Disease Alliance (TBDA), Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Food and Drug Administration (FDA), European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), World Health Organization (WHO), Pharmaceutical Research and Manufacturers of America (PhRMA), National Health Service (NHS), Company Website, Annual Reports, SEC Filings, Investor Presentation, Press Releases, Paid Data Sources, Wissen Research Analysis
1.INTRODUCTION
1.1 MARKET DEFINITION
1.1.1 INCLUSIONS & EXCLUSIONS
1.2 KEY OBJECTIVES OF THE STUDY
1.3 SCOPE OF THE STUDY
1.3.1 MARKETS COVERED
1.4 KEY STAKEHOLDERS
1.5 CURRENCIES CONSIDERED
2. RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.2 MARKET SIZE ESTIMATION
2.2.1 TOTAL MARKET SIZE: LYME DISEASE TREATMENT MARKET
2.2.2 GEOGRAPHICAL MARKET ASSESSMENT (BY REGION AND COUNTRY)
2.2.3 MARKET SEGMENT ASSESSMENT
2.2.4 GROWTH FORECAST
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 SCOPE-RELATED LIMITATIONS
2.6.2 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3. EXECUTIVE SUMMARY AND PREMIUM CONTENT
3.1 EXECUTIVE SUMMARY
3.1.1 LYME DISEASE TREATMENT MARKET, BY TYPE (2024 VS 2030, USD MILLION)
3.1.2 LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2024 VS 2030, USD MILLION)
3.1.3 LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2024 VS 2030, USD MILLION)
3.1.4 LYME DISEASE TREATMENT MARKET, BY GENDER (2024 VS 2030, USD MILLION)
3.1.5 LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2024 VS 2030, USD MILLION)
3.1.6 LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2024 VS 2030, USD MILLION)
3.1.7 GEOGRAPHIC SNAPSHOT OF LYME DISEASE TREATMENT MARKET
3.1.8 PROMINENT PLAYERS IN LYME DISEASE TREATMENT MARKET
3.2 PREMIUM CONTENT
3.2.1 LYME DISEASE TREATMENT MARKET OVERVIEW
3.2.2 NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY PRODUCT AND STAGES OF DISEASE (2023)
3.2.3 GEOGRAPHIC MIX: LYME DISEASE TREATMENT MARKET
4. OVERVIEW OF LYME DISEASE
4.1 INTRODUCTION
4.2 EPIDEMIOLOGY OF LYME DISEASE
4.2.1 NORTH AMERICA
4.2.2 EUROPE
4.2.3 ASIA-PACIFIC
4.2.4 GLOBAL OVERVIEW
4.3 PATHOPHYSIOLOGY
4.3.1 DISEASE TRANSMISSION
4.3.2 LYME DISEASE MECHANISM
4.4 CLINICAL MANIFESTATIONS OF LYME DISEASE
4.5 DIAGNOSIS OF LYME DISEASE
4.5.1 CLINICAL DIAGNOSIS
4.5.2 LABORATORY DIAGNOSIS
4.6 TREATMENT FOR LYME DISEASE
4.6.1 ANTIBIOTIC THERAPY
4.6.2 SYMPTOMATIC TREATMENT
4.7 PREVENTION OF LYME DISEASE
4.8 INDUSTRY TRENDS AND FUTURE DIRECTIONS IN LYME DISEASE
4.8.1 RESEARCH AND DEVELOPMENT:
4.8.2 CLINICAL TRIAL ANALYSIS FOR LYME DISEASE TREATMENT:
4.8.3 PUBLIC HEALTH INITIATIVES:
5. MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MARKET DRIVERS
5.1.1.1 INCREASING PREVALENCE AN DINCIDENCE OF LYME DISEASE TO DRIVE THE TREATMENT MARKET
5.1.1.2 INCREASED AWARENESS AMONG HEALTHCARE PROVIDERS AND THE GENERAL PUBLIC ABOUT LYME DISEASE
5.1.1.3 INNOVATIONS IN DIAGNOSTIC TOOLS TO BOLSTER GROWTH IN THE LYME DISEASE TREATMENT MARKET
5.1.1.4 SIGNIFICANT INVESTMENTS IN R&D FOR NEW THERAPIES, VACCINES, AND TREATMENT METHODOLOGIES TO DRIVE THE MARKET
5.1.2 RESTRAINTS
5.1.2.1 INCREASING PREVALENCE AN DINCIDENCE OF LYME DISEASE TO DRIVE THE TREATMENT MARKET
5.1.3 KEY BARRIERS/CHALLENGES TO MARKET
5.1.3.1REGULATORY BARRIERS
5.1.3.2FINANCIAL BARRIERS
5.1.3.3 MARKET BARRIERS
5.1.3.4CLINICAL AND SCIENTIFIC BARRIERS
5.1.3.5 PUBLIC PERCEPTION AND ADVOCACY
5.1.3.6CONSUMER CONCERNS
5.1.3.7 INTELLECTUAL PROPERTY AND LEGAL BARRIERS
5.1.3.8 POST-MARKET CHALLENGES
5.2 MARKET PENETRATION STRATEGY
5.3 PRICING STRATEGY
5.4 PATENT ANALYSIS
5.4.1 SUMMARY
5.4.2 APPLICATION AND ISSUED TREND
5.4.3 SIMPLE LEGAL STATUS
5.4.4 PATENT TYPE
5.4.5 PATENT APPLICATION, BY GEOGRAPHY (TOP COUNTRIES OF ORIGIN)
5.4.6 APPLICATION TREND IN TOP COUNTRIES
5.4.7 KEY TECHNOLOGIES
5.4.8 APPLICATION TREND OF KEY TECHNOLOGIES
5.4.9 TOP ASSIGNEES
5.4.10 TECHNOLOGY FOCUS OF TOP ASSIGNEES
5.4.11 MOST CITED PATENTS
5.4.12 PATENTS BY CONCEPTS
5.5 CLINICAL TRIAL ANALYSIS
5.5.1 INTRODUCTION
5.5.2 ANALYSIS BY TRIAL REGISTRATION YEAR
5.5.3 ANALYSIS BY PHASE OF DEVELOMENT
5.5.4 ANALYSIS BY NUMBER OF PATIENTS ENROLLED
5.5.5 ANALAYSIS BY STATUS OF TRIAL
5.5.6 ANALYSIS BY KEY SPONSERS
5.5.7 ANALYSIS BY STUDY DESIGN
5.5.8 ANALYSIS BY GEOGRAPHY DISTRIBUTION
5.5.9 ANALYSIS BY DRUG USAGE TYPE
5.5.10 ANALYSIS BY ROUTE OF ADMINISTRATION
5.5.11 ANALYSIS BY TYPE OF THERAPEUTIC AGENT
5.6 STRENGTHS AND WEAKNESS TO BE CONSIDERED
5.6.1 PRODUCT: STRENGTHS AND WEAKNESS
5.6.1.1 PRODUCT STRENGTHS
5.6.1.2 PRODUCT WEAKNESS
5.6.2 MARKET: STRENGTHS AND WEAKNESS
5.6.2.1MARKET STRENGTHS
5.6.2.2 MARKET WEAKNESS
5.6.3 ORGANIZATIONAL: STRENGTHS AND WEAKNESS
5.6.3.1 ORGANIZATIONAL STRENGTHS
5.6.3.2 ORGANIZATIONAL WEAKNESS
5.6.4 STRATEGIC AND OPERATIONAL: STRENGTHS AND WEAKNESS
5.6.4.1 STRATEGIC AND OPERATIONAL STRENGTHS
5.6.4.2 STRATEGIC AND OPERATIONAL WEAKNESS
5.7 VALUE CHAIN ANALYSIS
6. LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE
6.1 INTRODUCTION
6.2 ANTIBIOTICS
6.3 ADJUNCT THERAPEUTICS
6.4 EXPERIMENTAL AND NOVEL THERAPEUTICS
7. LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE
7.1 INTRODUCTION
7.2 EARLY-STAGE LYME DISEASE
7.3 DISSEMINATED LYME DISEASE
7.4 CHRONIC LYME DISEASE
8. LYME DISEASE TREATMENT MARKET, BY GENDER
8.1 INTRODUCTION
8.2 MALE
8.3 FEMALE
9. LYME DISEASE TREATMENT MARKET, BY AGE GROUP
9.1 INTRODUCTION
9.2 CHILDREN
9.3 ADULTS
9.4 ELDERLY
10. LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS
10.1 INTRODUCTION
10.2 PRIMARY CARE
10.3 INFECTIOUS DISEASE SPECIALISTS
10.4 RESEARCH INSTITUTIONS
10.5 OTHER HEALTHCARE SETTINGS
11. LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
11.1 INTRODUCTION
11.2 HOSPITALS
11.3 CLINICS
11.4 RETAIL PHARMACIES
11.5 ONLINE PHARMACIES
12. LYME DISEASE TREATMENT MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.3 EUROPE
12.4 ASIA PACIFIC
12.5 LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.7 KEY FINDINGS BASED ON MARKET SIZING AND GROWTH FORECAST
12.7.1 POTENTIAL FOR INVESTIGATIONAL DRUG CANDIDATES DURING THE FORECAST PERIOD
12.7.2 ASCERTAINING THE REVENUE PROJECTIONS OF THE VACCINES POST LAUNCH OF THE PRODUCT
13. COMPANY PROFILES
13.1 GSK PLC.
13.1.1 BUSINESS OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCT OFFERING
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.2.1 BUSINESS OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCT OFFERING
13.3 MASSBIOLOGICS
13.3.1 BUSINESS OVERVIEW
13.3.2 PRODUCTS
13.3.3 RECENT DEVELOPMENT
13.4 MODERNA, INC.
13.4.1 BUSINESS OVERVIEW
13.4.2 FINANCIAL SNAPSHOT: MODERNA INC. (2023)
13.4.3 PRODUCTS
13.4.4 RECENT DEVELOPMENT
13.5 PFIZER INC.
13.5.1 BUSINESS OVERVIEW
13.5.2 FINANCIAL SNAPSHOT: PFIZER INC. (2023)
13.5.3 PRODUCTS
13.5.4 RECENT DEVELOPMENT
13.6 TARSUS PHARMACEUTICALS, INC.
13.6.1 BUSINESS OVERVIEW
13.6.2FINANCIAL SNAPSHOT: TARSUS PHARMACEUTICALS, INC. (2023)
13.6.3 PRODUCTS
13.6.4 RECENT DEVELOPMENT
13.7 CORTENE, INC.
13.7.1 BUSINESS OVERVIEW
13.7.2 PRODUCTS
13.7.3 RECENT DEVELOPMENT
13.8 CYANVAC LLC
13.8.1 BUSINESS OVERVIEW
13.8.2 PRODUCTS
13.8.3 RECENT DEVELOPMENT
13.9 AEGIS LIFE INC.
13.9.1 BUSINESS OVERVIEW
13.9.2 PRODUCTS
14. COMPETITIVE LANDSCAPE
14.1 KEY PLAYERS IN LYME DISEASE TREATMENT
14.2 EMERGING TECHNOLOGY: KEY PLAYERS PIPELINE
15. APPENDIX
15.1 INDUSTRY SPEAK: KEY INSIGHTS FROM PRIMARY INTERVIEWS
15.2 DISCUSSION GUIDE
15.2.1 MARKET OVERVIEW
15.2.2 MARKET SIZING AND SPLIT SHARES
15.2.3 COMPETITIVE LANDSCAPE
15.3 AVAILABLE CUSTOMIZATION OPTION
15.4 ADJACENT MARKET STUDIES
15.5 AUTHORS OF THE STUDY
LIST OF FIGURES
FIGURE 1: LYME DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 2: RESEARCH DESIGN
FIGURE 3: PRIMARY SOURCES
FIGURE 4: PRIMARY PARTICIPANTS FROM DEMAND AND SUPPLY SIDE
FIGURE 5: BREAKDOWN OF PRIMARY PARTICIPANTS (SUPPLY SIDE)
FIGURE 6: BREAKDOWN OF PRIMARY PARTICIPANTS (DEMAND SIDE)
FIGURE 7: SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8: REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 9: SUPPLY SIDE MARKET SIZE ESTIMATION: COMPANY SHARE ANALYSIS
FIGURE 10: SCENARIO-BASED MARKET SIZE ESTIMATION FOR EMERGING VACCINES & NOVEL THERAPEUTICS
FIGURE 11: CAGR PROJECTIONS FROM MARKET DYNAMICS ANALYSIS (2024-2030)
FIGURE 12: CAGR PROJECTIONS PARAMETERS (2024 – 2030)
FIGURE 13: DATA TRIANGULATION METHODOLOGY
FIGURE 14: RISING INCIDENCE OF LYME DISEASE TO DRIVE THE MARKET
FIGURE 15: ANTIBIOTICS TO ACOUNT FOR LARGEST SHARE WHILE EXPERIMENTAL & NOVEL THERAPEUTICS TO GROW AT HIGHEST CAGR
FIGURE 16: NORTH AMERICA & EUROPE TO DOMINATE THE MARKET
FIGURE 17: DISEASE MECHANISM OF LYME DISEASE: BORRELIA BURGDORFERI
FIGURE 18: DIFFERENT APPROACHES INCORPORATED INTO NOVEL PRICING AND PAYMENT MODELS
FIGURE 19: KEY FACTORS IN VALUE-BASED PRICING FOR THE PHARMACEUTICAL INDUSTRY
FIGURE 20: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY TRIAL REGISTRATION YEAR
FIGURE 21: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY PHASE OF DEVELOPMENT
FIGURE 22: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY NUMBER OF PATEINTS ENROLLED AND PHASE OF DEVELOPMENT
FIGURE 23: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY TRIAL STATUS
FIGURE 24: CLINICAL TRIAL ANALYSIS: ANALYSIS BY KEY SPONSERS
FIGURE 25: CLINICAL TRIAL ANALYSIS: ANALYSIS BY KEY SPONSERS AND CLINICAL TRIAL ANALYSIS
FIGURE 26: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY STUDY DESIGN
FIGURE 27: CLINICAL TRIAL ANALYSIS: DISTRIBUTION BY GEOGRAPHY
FIGURE 28: CLINICAL TRIAL ANALYSIS: ANALYSIS BY USAGE TYPE
FIGURE 29: CLINICAL TRIAL ANALYSIS: ANAYSIS BY ROUTE OF ADMINISTRATION
FIGURE 30: CLINICAL TRIAL ANALYSIS: ANALYSIS BY TYPE OF THERAPEUTIC AGENT
FIGURE 31: LYME DISEASE MARKET SNAPSHOT, BY PRODUCT
FIGURE 32: LYME DISEASE MARKET SNAPSHOT, BY REGION
FIGURE 33: LYME DISEASE MARKET SNAPSHOT, BY STAGES OF DISEASES
FIGURE 34: LYME DISEASE MARKET SNAPSHOT, BY GENDER
FIGURE 35: LYME DISEASE MARKET SNAPSHOT, BY AGE GROUP
FIGURE 36: LYME DISEASE MARKET SNAPSHOT, BY HEALTHCARE SETTINGS
FIGURE 37: LYME DISEASE MARKET SNAPSHOT, BY DISTRIBUTION CHANNEL
FIGURE 38: LYME DISEASE MARKET SNAPSHOT, BY REGION
FIGURE 39: LYME NUMBER OF HUMAN REPORTED LYME DISEASE CASES (2015 – 2023)
FIGURE 40: LABORATORY REPORTS OF LYME DISEASE IN ENGLAND AND WALES: ANNUAL TOTALS AND RATES, 2013 TO 2021
FIGURE 41: SCENARIO-BASED MARKET SIZING FOR LYME VACCINES AND NOVEL THERAPEUTICS
LIST OF TABLES
TABLE 1: STANDARD CURRENCY COVERSION RATE
TABLE 2: ASSUMPTIONS OF THE STUDY
TABLE 3: RISK ASSESSMENT: LYME DISEASE TREATMENT MARKET
TABLE 4: HISTORY OF LYME DISEASE
TABLE 5: PREVALENCE OF LYME DISEASE
TABLE 6: FUTURE OF LYME DISEASE
TABLE 7: INCIDENCE OF LYME DISEASE IN SELECTED U.S. STATES (2018)
TABLE 8: LYME DISEASE INCIDENCE IN SELECTED EUROPEAN COUNTRIES
TABLE 9: INCIDENCE TRENDS IN THE UNITED STATES
TABLE 10: INCIDENCE TRENDS BASED ON AGE GROUPS
TABLE 11: LIFE STAGES AND INFECTION RISK OF BLACK LEGGED TICKS
TABLE 12: TRANSMISSION OF LYME DISEASE BY TICK TYPE AND REGION
TABLE 13: GLOBAL LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 14: EXAMPLE OF ANTIBIOTICS USED IN LYME DISEASE TREATMENT
TABLE 15: GLOBAL LYME DISEASE TREATMENT MARKET FOR ANTIBIOTICS, BY REGION (2023 – 2030, USD MILLION)
TABLE 16: EXAMPLE OF ADJUNCT THERAPEUTICS USED IN LYME DISEASE TREATMENT
TABLE 17: GLOBAL LYME DISEASE TREATMENT MARKET FOR ADJUNCT THERAPEUTICS, BY REGION (2023 – 2030, USD MILLION)
TABLE 18: ONGOING IMPORTANT CLINICAL TRIALS FOR EXPERIMENTAL AND NOVEL THERAPEUTIC LYME DISEASE TREATMENT
TABLE 19: GLOBAL LYME DISEASE TREATMENT MARKET FOR ADJUNCT THERAPEUTICS, BY REGION (2023 – 2030, USD MILLION)
TABLE 20: GLOBAL LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 21: GLOBAL EARLY-STAGE LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 22: GLOBAL DISSEMINATED LYME DISEASE DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 23: GLOBAL CHRONIC LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 24: DISTRIBUTION OF CLAIM LINES WITH LYME DISEASE DIAGNOSES BY AGE GROUP AND GENDER (2022)
TABLE 25: GLOBAL LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 26: GLOBAL LYME DISEASE TREATMENT MARKET FOR MALE, BY REGION (2023 – 2030, USD MILLION)
TABLE 27: GLOBAL LYME DISEASE TREATMENT MARKET FOR FEMALE, BY REGION (2023 – 2030, USD MILLION)
TABLE 28: DISTRIBUTION OF CLAIM LINES WITH LYME DISEASE DIAGNOSES BY AGE GROUP (2018 – 2022)
TABLE 29: GLOBAL LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 30: GLOBAL LYME DISEASE TREATMENT MARKET FOR CHILDREN, BY REGION (2023 – 2030, USD MILLION)
TABLE 31: GLOBAL LYME DISEASE TREATMENT MARKET FOR ADULT, BY REGION (2023 – 2030, USD MILLION)
TABLE 32: GLOBAL LYME DISEASE TREATMENT MARKET FOR ELDERLY POPULATION, BY REGION (2023 – 2030, USD MILLION)
TABLE 33: GLOBAL LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 34: ACTIVE PRIMARY CARE PHYSICIANS BY SPECIALTY IN 2021
TABLE 35: GLOBAL PRIMARY CARE LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 36: GLOBAL INFECTIOUS DISEASE SECIALISTS LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 37: GLOBAL RESEARCH INSTITUTIONS LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 38: GLOBAL OTHER HEALTHCARE SETTINGS LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 39: GLOBAL LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2023 – 2030, USD MILLION)
TABLE 40: GLOBAL LYME DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION (2023 – 2030, USD MILLION)
TABLE 41: GLOBAL LYME DISEASE TREATMENT MARKET FOR CLINICS, BY REGION (2023 – 2030, USD MILLION)
TABLE 42: GLOBAL LYME DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION (2023 – 2030, USD MILLION)
TABLE 43: GLOBAL LYME DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION (2023 – 2030, USD MILLION)
TABLE 44: GLOBAL LYME DISEASE TREATMENT MARKET, BY REGION (2023 – 2030, USD MILLION)
TABLE 45: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 46: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 47: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 48: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 49: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 50: NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2023 – 2030, USD MILLION)
TABLE 51: EUROPE LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 52: EUROPE LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 53: EUROPE LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 54: EUROPE LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 55: EUROPE LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 56: EUROPE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2023 – 2030, USD MILLION)
TABLE 57: ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 58: ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 59:ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 60:ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 61:ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 62: ASIA PACIFIC LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2023 – 2030, USD MILLION)
TABLE 63:LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 64:LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 65:LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 66: LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 67: LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 68: LATIN AMERICA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2023 – 2030, USD MILLION)
TABLE 69: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE (2023 – 2030, USD MILLION)
TABLE 70: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY STAGES OF DISEASE (2023 – 2030, USD MILLION)
TABLE 71: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY GENDER (2023 – 2030, USD MILLION)
TABLE 72: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY AGE GROUP (2023 – 2030, USD MILLION)
TABLE 73: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY HEALTHCARE SETTINGS (2023 – 2030, USD MILLION)
TABLE 74: MIDDLE EAST & AFRICA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNELS (2023 – 2030, USD MILLION)
